دورية أكاديمية
Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
| العنوان: | Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report |
|---|---|
| المؤلفون: | Sadananda Rao Manjunath, Ganapathi Ramanan, Vidyasagar Devaprasad Dedeepiya, Hiroshi Terunuma, Xuewen Deng, Subramani Baskar, Rajappa Senthilkumar, Paramasivam Thamaraikannan, Thangavelu Srinivasan, Senthilkumar Preethy, Samuel J.K. Abraham |
| المصدر: | Case Reports in Oncology, Vol 5, Iss 1, Pp 114-118 (2012) |
| بيانات النشر: | Karger Publishers, 2012. |
| سنة النشر: | 2012 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Recurrent ovarian carcinoma, Natural killer cells (CD3–CD56+), Activated T lymphocytes (CD3+CD56+), Autologous immune enhancement therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Current therapeutic modalities for ovarian cancer such as chemotherapy, radiotherapy and surgery have been reported to yield only marginal success in improving survival rates of patients and have associated adverse effects. We report here a case of recurrent stage IV ovarian cancer, treated with cell-based autologous immune enhancement therapy (AIET) along with chemotherapy and followed up for 18 months. A 54-year-old female was diagnosed with a recurrence of ovarian carcinoma 1 year after initial surgical removal followed by chemotherapy for stage IIIC ovarian carcinoma. When diagnosed in 2010 with recurrence, she had liver and spleen metastases with a CA-125 level of 243 U/ml and a stage IV clinical status. Six infusions of AIET using autologous in vitro expanded and activated natural killer (NK) cells (CD3–CD56+) and activated T lymphocytes (CD3+CD56+) were administered in combination with 6 cycles of chemotherapy with carboplatin and doxorubicin. Following this treatment, CA-125 decreased to 4.7 U/ml along with regression of the metastatic lesions and an improved quality of life. No adverse reactions were reported after the AIET transfusions. Eighteen months of follow-up revealed a static nonprogressive disease. Combining AIET with chemotherapy and other conventional treatments has been found to be effective in our experience, as reported earlier, even in patients with advanced ovarian cancer, and we recommend this strategy be considered in treating similar cases. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1662-6575 00033731 |
| Relation: | http://www.karger.com/Article/FullText/337319; https://doaj.org/toc/1662-6575 |
| DOI: | 10.1159/000337319 |
| URL الوصول: | https://doaj.org/article/b129ecc1b955441482c3df44e297c4bd |
| رقم الأكسشن: | edsdoj.b129ecc1b955441482c3df44e297c4bd |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16626575 00033731 |
|---|---|
| DOI: | 10.1159/000337319 |